VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ISA 2022 | Time to next treatment as a prognostic marker in patients with AL amyloidosis

Despina Fotiou, MD, PhD, University of Athens, Athens, Greece, comments on the impact of time to next treatment in AL amyloidosis, highlighting the importance of considering multiple parameters when making the decision to change treatment. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter